NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.08 USD
+0.04 (1.96%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Brokerage Reports
0 items in cart
NRx Pharmaceuticals, Inc. [NRXP]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Adjusting Our Cash Burn Down, Extending Runway
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Announces Completion of Enrollment - P2B/3 NRX-101 in Suicidal Treatment-Resistant Bipolar Depression
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Looking For Hope to Spring in 2024; Reiterate Buy and $2.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRXP Signs Agreement Access to Data Shows Efficacy Safety of IV Ketamine for the Treatment of Suicidal Depression
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRx Pharmaceuticals Nephron Pharmaceuticals announce a Joint Agreement to Develop IV Ketamine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Study May Proceed (letter) - A New Way to Treat Pain
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Strategic Change Could Accelerate NRX-100?s Regulatory Path; Reiterate Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRX-101 - IND Filed for Pain Indication but it?s Early Days
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Factoring in Future Dilution - Lowering Price Target - $9.0 to $2.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRx Licenses IP for NRX-101 for Chronic Pain
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRx Licenses NRX-101 to Lotus - $330M in Milestones
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRX-101?s Pathway May Be Poised to Accelerate; Reiterate Buy and $2.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V